| pubmed-article:14520423 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C0032520 | lld:lifeskim |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C0086589 | lld:lifeskim |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C1511791 | lld:lifeskim |
| pubmed-article:14520423 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:14520423 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:14520423 | pubmed:dateCreated | 2003-10-1 | lld:pubmed |
| pubmed-article:14520423 | pubmed:abstractText | Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation. | lld:pubmed |
| pubmed-article:14520423 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14520423 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14520423 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14520423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14520423 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14520423 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:14520423 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:BoccadoroMM | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:SantoroAA | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:MajolinoII | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:FarinaLL | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:CorradiniPP | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:MalnatiMM | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:DeanS JSJ | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:LadettoMM | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:VoenaCC | lld:pubmed |
| pubmed-article:14520423 | pubmed:author | pubmed-author:MontefuscoVV | lld:pubmed |
| pubmed-article:14520423 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14520423 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:14520423 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14520423 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14520423 | pubmed:pagination | 791-3 | lld:pubmed |
| pubmed-article:14520423 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:meshHeading | pubmed-meshheading:14520423... | lld:pubmed |
| pubmed-article:14520423 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14520423 | pubmed:articleTitle | Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. | lld:pubmed |
| pubmed-article:14520423 | pubmed:affiliation | Laboratorio Ematologia Molecolare, Istituto Scientifico HS Raffaele, Milano, Italy. | lld:pubmed |
| pubmed-article:14520423 | pubmed:publicationType | Journal Article | lld:pubmed |
